Search

Your search keyword '"Di Maio M"' showing total 1,316 results
Start Over Author "Di Maio M"
1,316 results on '"Di Maio M"'

51. Intravenous antiplatelet therapy with cangrelor vs. tirofiban in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention

Author

Centore, M, primary, Silverio, A, additional, Scudiero, F, additional, Di Maio, M, additional, Muraca, I, additional, Dossi, F, additional, Petrini, F, additional, Brenca, D, additional, Maiellaro, F, additional, Attisano, T, additional, Parodi, G, additional, Musumeci, G, additional, and Galasso, G, additional

Published
2022
Full Text
View/download PDF

54. 704TiP SAR445256 (KY1044) in combination with atezolizumab in patients (pts) with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)

Author

Patel, M., primary, Ascierto, P.A., additional, Thistlethwaite, F., additional, Adkins, D.R., additional, Meucci Villaflor, V., additional, Galizia, D., additional, Calabro, L., additional, Di Maio, M., additional, D'Ambrosio, C., additional, Bertolini, A., additional, Damato, A., additional, Deantonio, C., additional, Yang, Y., additional, Kurup, D., additional, and Abbadessa, G., additional

Published
2022
Full Text
View/download PDF

55. 590P Ki67 as a predictor of response to PARP inhibitors in platinum sensitive BRCA wild type ovarian cancers: MITO 37 retrospective study

Author

Tuninetti, V., primary, Ghisoni, E., additional, Pignata, S., additional, Picardo, E., additional, Raspagliesi, F., additional, Andreetta, C., additional, Maldi, E., additional, Artioli, G., additional, Mammoliti, S., additional, Roccio, M., additional, Sikokis, A., additional, Biglia, N., additional, Parisi, A., additional, Mandato, V.D., additional, Carella, C., additional, Cormio, G., additional, Marinaccio, M., additional, Scotto, G., additional, Di Maio, M., additional, and Valabrega, G., additional

Published
2022
Full Text
View/download PDF

56. 1626P Time trends (2012-2016 vs 2017-2021) in health-related quality of life (QoL) assessment and reporting in oncology: A systematic review of randomized phase III trials

Author

Marandino, L., primary, Trastu, F., additional, Ghisoni, E., additional, Lombardi, P., additional, Mariniello, A., additional, Reale, M.L., additional, Aimar, G., additional, Audisio, M., additional, Bungaro, M., additional, Caglio, A., additional, Di Liello, R., additional, Gamba, T., additional, Gargiulo, P., additional, Paratore, C., additional, Rossi, A., additional, Tuninetti, V., additional, Turco, F., additional, Perrone, F., additional, and Di Maio, M., additional

Published
2022
Full Text
View/download PDF

60. 1349P A prospective study on clinicians’ attitudes and survival outcomes for patients with NSCLC and poor performance status in the immunotherapy era: PICASO study (GOIRC-04-2020)

Author

Facchinetti, F., Camerini, A., Bennati, C., Bordi, P., De Carlo, E., Mazzoni, F., Metro, G., Bertolini, F., Longo, L., Ricciardi, S., Pilotto, S., Bria, E., Giardina, D., Passiglia, F., Cortinovis, D.L., Scotti, V., Novello, S., Tognetto, M., Di Maio, M., and Tiseo, M.

Published
2024
Full Text
View/download PDF

62. Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study

Author

Nuzzo, F., Gallo, C., Lastoria, S., Di Maio, M., Piccirillo, M.C., Gravina, A., Landi, G., Rossi, E., Pacilio, C., Labonia, V., Di Rella, F., Bartiromo, A., Buonfanti, G., De Feo, G., Esposito, G., D'Aniello, R., Maiolino, P., Signoriello, S., De Maio, E., Tinessa, V., Colantuoni, G., De Laurentiis, M., D'Aiuto, M., Di Bonito, M., Botti, G., Giordano, P., Daniele, G., Morabito, A., Normanno, N., de Matteis, A., and Perrone, F.

Published
2012
Full Text
View/download PDF

63. 50P Direct-acting oral anticoagulants prescribing pattern in patients with gynaecological cancer: Results of a survey among Italian oncologists belonging to MITO group and AIOM society

Author

Tuninetti, V., primary, Milani, A., additional, Pignata, S., additional, Lorusso, D., additional, Castaldo, D., additional, De Giorgi, U.F.F., additional, Savarese, A., additional, Biglia, N., additional, Scandurra, G., additional, Testa, S., additional, Mangili, G., additional, Di Maio, M., additional, Turinetto, M., additional, Mammoliti, S., additional, Scotto, G., additional, Artioli, G., additional, and Valabrega, G., additional

Published
2022
Full Text
View/download PDF

64. Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies

Author

Russo, A., primary, Incorvaia, L., additional, Capoluongo, E., additional, Tagliaferri, P., additional, Gori, S., additional, Cortesi, L., additional, Genuardi, M., additional, Turchetti, D., additional, De Giorgi, U., additional, Di Maio, M., additional, Barberis, M., additional, Dessena, M., additional, Del Re, M., additional, Lapini, A., additional, Luchini, C., additional, Jereczek-Fossa, B.A., additional, Sapino, A., additional, Cinieri, S., additional, Beretta, Giordano, additional, Bella, Maria Angela, additional, Bracarda, Sergio, additional, Colombo, Nicoletta, additional, Conteduca, Vincenza, additional, Del Mastro, Lucia, additional, Galvano, Antonio, additional, Gristina, Valerio, additional, Guarneri, Valentina, additional, La Verde, Nicla, additional, Lorusso, Domenica, additional, Marchetti, Paolo, additional, Normanno, Nicola, additional, Ottini, Laura, additional, Pensabene, Matilde, additional, Pignata, Sandro, additional, Procopio, Giuseppe, additional, Ricevuto, Enrico, additional, Silvestris, Nicola, additional, Tassone, Pierfrancesco, additional, Tucci, Marcello, additional, Donato, Vittorio, additional, Carrara, Silvia, additional, Paiella, Salvatore, additional, Gentilini, Oreste, additional, Gunelli, Roberta, additional, Nicolis, Fabrizio, additional, Buttitta, Fiamma, additional, Colecchia, Maurizio, additional, Fassan, Matteo, additional, Malapelle, Umberto, additional, Marchetti, Antonio, additional, Marchiò, Caterina, additional, Scarpa, Aldo, additional, Truini, Mauro, additional, Zamboni, Giuseppe, additional, Gion, Massimo, additional, Trevisiol, Chiara, additional, Gronchi, Alessandro, additional, Danesi, Romano, additional, Di Marco, Vito, additional, Carrera, Paola, additional, Ghiorzo, Paola, additional, Pasini, Barbara, additional, Varesco, Liliana, additional, Artibani, Walter, additional, Ludovico, Giuseppe, additional, Campanella, Ornella, additional, Vatrano, Simona, additional, and Tagliafico, Enrico, additional

Published
2022
Full Text
View/download PDF

66. MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis

Author

Musacchio, L., Valsecchi, A. A., Salutari, Vanda, Valabrega, G., Camarda, Floriana, Tuninetti, V., Giannone, G., Bartoletti, M., Marchetti, Claudia, Pignata, S., Fagotti, Anna, Scambia, Giovanni, Di Maio, M., Lorusso, Domenica, Salutari V., Camarda F., Marchetti C. (ORCID:0000-0001-7098-8956), Fagotti A. (ORCID:0000-0001-5579-335X), Scambia G. (ORCID:0000-0003-2758-1063), Lorusso D., Musacchio, L., Valsecchi, A. A., Salutari, Vanda, Valabrega, G., Camarda, Floriana, Tuninetti, V., Giannone, G., Bartoletti, M., Marchetti, Claudia, Pignata, S., Fagotti, Anna, Scambia, Giovanni, Di Maio, M., Lorusso, Domenica, Salutari V., Camarda F., Marchetti C. (ORCID:0000-0001-7098-8956), Fagotti A. (ORCID:0000-0001-5579-335X), Scambia G. (ORCID:0000-0003-2758-1063), and Lorusso D.

Abstract

Background: Low grade serous carcinoma of the ovary and peritoneum (LGSC) is characterized by low response rates to chemotherapy and by MAPK pathway alterations. Phase II/III clinical trials tested different MEK inhibitors (MEKis) in this complex malignancy, with heterogenous results. Purpose of this systematic review and meta-analysis is to define activity and efficacy of these agents and explore differences in clinical outcomes related to RAS/RAF mutational status. Methods: In March 2022, we searched Pubmed, Web of Science, Scopus, and the major conference proceedings (ASCO, ESMO) for randomized and non-randomized clinical trials evaluating MEKi as single agent in recurrent LGSC. The screening was performed independently by two reviewers. Objective response rate (ORR) and progression-free survival (PFS) data were extracted, and RevMan 5.3 software was used for statistical analysis. Results: A total of 4 clinical trials involving 648 patients were included. In the intention-to-treat population, use of a MEK inhibitor was not associated with a significant improvement in PFS, with a pooled Hazard Ratio equal to 0.75 (95 % CI: 0.30 – 1.86, P = 0.54). Heterogeneity was significant (I2 = 92 %; P = 0.0004). In the overall study population, the pooled odds ratio of ORR for MEKis compared to control treatment was 2.61 (95 % CI: 0.65 – 10.54, P = 0.18). Specifically, ORR was 20.12 % in patients treated with MEKis compared to 9.09 % in women receiving standard treatment. Heterogeneity was significant (I2 = 85 %; P = 0.009). Conclusions: Although no statistically significant improvement in PFS was demonstrated, the available data show clear signals of activity, at least for some MEKis.

Published
2022

72. P97 VALIDATION OF THE ACADEMIC RESEARCH CONSORTIUM HIGH BLEEDING RISK CRITERIA IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: A SYSTEMATIC REVIEW AND METANALYSIS OF 10 STUDIES AND 67,862 PATIENTS

Author

Esposito, L, primary, Baldi, C, additional, Silverio, A, additional, Di Maio, M, additional, Cancro, F, additional, Buccheri, S, additional, De Luca, G, additional, Sarno, G, additional, Bellino, M, additional, Verdoia, M, additional, Vecchione, C, additional, and Galasso, G, additional

Published
2022
Full Text
View/download PDF

74. Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors

Author

Ricci, C., Pusceddu, S., Prinzi, N., Tafuto, S., Ibrahim, T., Filice, A., Brizzi, M. P., Panzuto, F., Baldari, S., Grana, C. M., Campana, D., Davi, M. V., Giuffrida, D., Zatelli, M. C., Partelli, S., Razzore, P., Marconcini, R., Massironi, S., Gelsomino, F., Faggiano, A., Giannetta, E., Bajetta, E., Grimaldi, F., Cives, M., Cirillo, F., Perfetti, V., Corti, F., Giacomelli, L., Porcu, L., Di Maio, M., Seregni, E., Maccauro, M., Lastoria, S., Bongiovanni, A., Versari, A., Persano, I., Rinzivillo, M., Pignata, S. A., Rocca, P. A., Lamberti, G., Cingarlini, S., Puliafito, I., Ambrosio, M. R., Zanata, I., Bracigliano, A., Severi, S., Spada, F., Andreasi, V., Modica, R., Scalorbi, F., Milione, M., Sabella, G., Coppa, J., Casadei, R., Di Bartolomeo, M., Falconi, M., De Braud, F., Pusceddu, Sara, Prinzi, Natalie, Tafuto, Salvatore, Ibrahim, Toni, Filice, Angelina, Brizzi, Maria Pia, Panzuto, Francesco, Baldari, Sergio, Grana, Chiara M., Campana, Davide, Davì, Maria Vittoria, Giuffrida, Dario, Zatelli, Maria Chiara, Partelli, Stefano, Razzore, Paola, Marconcini, Riccardo, Massironi, Sara, Gelsomino, Fabio, Faggiano, Antongiulio, Giannetta, Elisa, Bajetta, Emilio, Grimaldi, Franco, Cives, Mauro, Cirillo, Fernando, Perfetti, Vittorio, Corti, Francesca, Ricci, Claudio, Giacomelli, Luca, Porcu, Luca, Di Maio, Massimo, Seregni, Ettore, Maccauro, Marco, Lastoria, Secondo, Bongiovanni, Alberto, Versari, Annibale, Persano, Irene, Rinzivillo, Maria, Pignata, Salvatore Antonio, Rocca, Paola Anna, Lamberti, Giuseppe, Cingarlini, Sara, Puliafito, Ivana, Ambrosio, Maria Rosaria, Zanata, Isabella, Bracigliano, Alessandra, Severi, Stefano, Spada, Francesca, Andreasi, Valentina, Modica, Roberta, Scalorbi, Federica, Milione, Massimo, Sabella, Giovanna, Coppa, Jorgelina, Casadei, Riccardo, Di Bartolomeo, Maria, Falconi, Massimo, de Braud, Filippo, Grana, Chiara M, and Davi, Maria Vittoria

Subjects
Male, Radiotherapy, Receptors, Peptide, General Medicine, sequence, Middle Aged, peptide receptors radionuclide therapy, everolimus, chemotherapy, Progression-Free Survival, NO, Peptide Receptor Radionuclide Therapy, Pancreatic Neoplasms, Neuroendocrine Tumors, receptor radionuclide therapy, enteropancreatic neuroendocrine tumors, progression free survival, Receptors, Peptide, Humans, Female, LS4_3, neuroendocrine tumors, sequence, everolimus, Retrospective Studies
Abstract

Importance: Data about the optimal timing for the initiation of peptide receptor radionuclide therapy (PRRT) for advanced, well-differentiated enteropancreatic neuroendocrine tumors are lacking. Objective: To evaluate the association of upfront PRRT vs upfront chemotherapy or targeted therapy with progression-free survival (PFS) among patients with advanced enteropancreatic neuroendocrine tumors who experienced disease progression after treatment with somatostatin analogues (SSAs). Design, setting, and participants: This retrospective, multicenter cohort study analyzed the clinical records from 25 Italian oncology centers for patients aged 18 years or older who had unresectable, locally advanced or metastatic, well-differentiated, grades 1 to 3 enteropancreatic neuroendocrine tumors and received either PRRT or chemotherapy or targeted therapy after experiencing disease progression after treatment with SSAs between January 24, 2000, and July 1, 2020. Propensity score matching was done to minimize the selection bias. Exposures: Upfront PRRT or upfront chemotherapy or targeted therapy. Main outcomes and measures: The main outcome was the difference in PFS among patients who received upfront PRRT vs among those who received upfront chemotherapy or targeted therapy. A secondary outcome was the difference in overall survival between these groups. Hazard ratios (HRs) were fitted in a multivariable Cox proportional hazards regression model to adjust for relevant factors associated with PFS and were corrected for interaction with these factors. Results: Of 508 evaluated patients (mean ([SD] age, 55.7 [0.5] years; 278 [54.7%] were male), 329 (64.8%) received upfront PRRT and 179 (35.2%) received upfront chemotherapy or targeted therapy. The matched group included 222 patients (124 [55.9%] male; mean [SD] age, 56.1 [0.8] years), with 111 in each treatment group. Median PFS was longer in the PRRT group than in the chemotherapy or targeted therapy group in the unmatched (2.5 years [95% CI, 2.3-3.0 years] vs 0.7 years [95% CI, 0.5-1.0 years]; HR, 0.35 [95% CI, 0.28-0.44; P

Published
2022

77. Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study

Author

Gobbini, E, Chiari, R, Pizzutillo, P, Bordi, P, Ghilardi, L, Pilotto, S, Osman, G, Cappuzzo, F, Cecere, F, Riccardi, F, Scotti, V, Martelli, O, Borra, G, Maiello, E, Rossi, A, Graziano, P, Gregorc, V, Casartelli, C, Sergi, C, Del Conte, A, Delmonte, A, Bareggi, C, Cortinovis, D, Rizzo, P, Tabbò, F, Rossi, G, Bria, E, Galetta, D, Tiseo, M, Di Maio, M, Novello, S, Gobbini E, Chiari R, Pizzutillo P, Bordi P, Ghilardi L, Pilotto S, Osman G, Cappuzzo F, Cecere F, Riccardi F, Scotti V, Martelli O, Borra G, Maiello E, Rossi A, Graziano P, Gregorc V, Casartelli C, Sergi C, Del Conte A, Delmonte A, Bareggi C, Cortinovis D, Rizzo P, Tabbò F, Rossi G, Bria E, Galetta D, Tiseo M, Di Maio M, Novello S., Gobbini, E, Chiari, R, Pizzutillo, P, Bordi, P, Ghilardi, L, Pilotto, S, Osman, G, Cappuzzo, F, Cecere, F, Riccardi, F, Scotti, V, Martelli, O, Borra, G, Maiello, E, Rossi, A, Graziano, P, Gregorc, V, Casartelli, C, Sergi, C, Del Conte, A, Delmonte, A, Bareggi, C, Cortinovis, D, Rizzo, P, Tabbò, F, Rossi, G, Bria, E, Galetta, D, Tiseo, M, Di Maio, M, Novello, S, Gobbini E, Chiari R, Pizzutillo P, Bordi P, Ghilardi L, Pilotto S, Osman G, Cappuzzo F, Cecere F, Riccardi F, Scotti V, Martelli O, Borra G, Maiello E, Rossi A, Graziano P, Gregorc V, Casartelli C, Sergi C, Del Conte A, Delmonte A, Bareggi C, Cortinovis D, Rizzo P, Tabbò F, Rossi G, Bria E, Galetta D, Tiseo M, Di Maio M, and Novello S.

Abstract

Purpose: Anaplastic lymphoma kinase (ALK) rearrangement confers sensitivity to ALK inhibitors (ALKis) in non-small-cell lung cancer (NSCLC). Although several drugs provided an impressive outcome benefit, the most effective sequential strategy is still unknown. We describe outcomes of real-life patients according to the treatment strategy received. Patients: We retrospectively collected 290 ALK rearranged advanced NSCLC diagnosed between 2011 and 2017 in 23 Italian institutions. Results: After a median follow-up of 26 months, PFS for crizotinib and a new generation ALKis were 9.4 [CI 95% 7.9–11.2] and 11.1 months [CI 95% 9.2–13.8], respectively, while TTF were 10.2 [CI 95% 8.5–12.6] and 11.9 months [CI 95% 9.7–17.4], respectively, being consistent across the different settings. The composed outcomes (the sum of PFS or TTF) in patients treated with crizotinib followed by a new generation ALKis were 27.8 months [CI 95% 24.3–33.7] in PFS and 30.4 months [CI 95% 24.7–34.9] in TTF. The median OS from the diagnosis of advanced disease was 39 months [CI 95% 31.8–54.5]. Patients receiving crizotinib followed by a new generation ALKis showed a higher median OS [57 months (CI 95% 42.0–73.8)] compared to those that did not receive crizotinib [38 months (CI 95% 18.6–NR)] and those who performed only crizotinib as target agent [15 months (CI 95% 11.3–34.0)] (P < 0.0001). Conclusion: The sequential administration of crizotinib and a new generation ALKis provided a remarkable clinical benefit in this real-life population, being an interesting option to consider in selected patients.

Published
2020

78. Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study

Author

Bersanelli, M, Buti, S, Giannarelli, D, Leonetti, A, Cortellini, A, Russo, G, Signorelli, D, Toschi, L, Milella, M, Pilotto, S, Bria, E, Proto, C, Marinello, A, Randon, G, Rossi, S, Vita, E, Sartori, G, D'Argento, E, Qako, E, Giaiacopi, E, Ghilardi, L, Bettini, A, Rapacchi, E, Mazzoni, F, Lavacchi, D, Scotti, V, Ciccone, L, De Tursi, M, Di Marino, P, Santini, D, Russano, M, Bordi, P, Di Maio, M, Audisio, M, Filetti, M, Giusti, R, Berardi, R, Fiordoliva, I, Cerea, G, Pizzutilo, E, Bearz, A, De Carlo, E, Cecere, F, Renna, D, Camisa, R, Caruso, G, Ficorella, C, Banna, G, Cortinovis, D, Brighenti, M, Garassino, M, Tiseo, M, Bersanelli M., Buti S., Giannarelli D., Leonetti A., Cortellini A., Russo G. L., Signorelli D., Toschi L., Milella M., Pilotto S., Bria E., Proto C., Marinello A., Randon G., Rossi S., Vita E., Sartori G., D'Argento E., Qako E., Giaiacopi E., Ghilardi L., Bettini A. C., Rapacchi E., Mazzoni F., Lavacchi D., Scotti V., Ciccone L. P., De Tursi M., Di Marino P., Santini D., Russano M., Bordi P., Di Maio M., Audisio M., Filetti M., Giusti R., Berardi R., Fiordoliva I., Cerea G., Pizzutilo E. G., Bearz A., De Carlo E., Cecere F., Renna D., Camisa R., Caruso G., Ficorella C., Banna G. L., Cortinovis D., Brighenti M., Garassino M. C., Tiseo M., Bersanelli, M, Buti, S, Giannarelli, D, Leonetti, A, Cortellini, A, Russo, G, Signorelli, D, Toschi, L, Milella, M, Pilotto, S, Bria, E, Proto, C, Marinello, A, Randon, G, Rossi, S, Vita, E, Sartori, G, D'Argento, E, Qako, E, Giaiacopi, E, Ghilardi, L, Bettini, A, Rapacchi, E, Mazzoni, F, Lavacchi, D, Scotti, V, Ciccone, L, De Tursi, M, Di Marino, P, Santini, D, Russano, M, Bordi, P, Di Maio, M, Audisio, M, Filetti, M, Giusti, R, Berardi, R, Fiordoliva, I, Cerea, G, Pizzutilo, E, Bearz, A, De Carlo, E, Cecere, F, Renna, D, Camisa, R, Caruso, G, Ficorella, C, Banna, G, Cortinovis, D, Brighenti, M, Garassino, M, Tiseo, M, Bersanelli M., Buti S., Giannarelli D., Leonetti A., Cortellini A., Russo G. L., Signorelli D., Toschi L., Milella M., Pilotto S., Bria E., Proto C., Marinello A., Randon G., Rossi S., Vita E., Sartori G., D'Argento E., Qako E., Giaiacopi E., Ghilardi L., Bettini A. C., Rapacchi E., Mazzoni F., Lavacchi D., Scotti V., Ciccone L. P., De Tursi M., Di Marino P., Santini D., Russano M., Bordi P., Di Maio M., Audisio M., Filetti M., Giusti R., Berardi R., Fiordoliva I., Cerea G., Pizzutilo E. G., Bearz A., De Carlo E., Cecere F., Renna D., Camisa R., Caruso G., Ficorella C., Banna G. L., Cortinovis D., Brighenti M., Garassino M. C., and Tiseo M.

Abstract

Objectives: In the most of cases, for non-small cell lung cancer (NSCLC) patients who progressed to previous immune checkpoint inhibitors (CKI) administered as first- or as second-line therapy, chemotherapy (CT) remains the only viable options in the absence of “druggable” mutations. We aimed to explore the efficacy of salvage chemotherapy after immunotherapy (SCAI) in advanced NSCLC patients. Materials and Methods: We designed a retrospective, multicenter study, involving 20 Italian centers, with the primary objective of describing the clinical outcome of advanced NSCLC patients treated with SCAI at the participating institutions from November 2013 to July 2019. The primary endpoint of the study was represented by overall survival (OS), defined as the time from CT initiation to death. Secondary outcome endpoints of the SCAI (progression free survival, PFS, objective response rate, ORR and toxicity) and explorative biomarkers (lactate dehydrogenase, LDH, and neutrophil-to-lymphocyte ratio, NLR during immunotherapy) were also analyzed. Results: In our study population of 342 NSCLC patients, SCAI obtained a median OS of 6.8 months (95 % confidence interval, CI 5.5–8.1), median PFS of 4.1 months (95 % CI 3.4−4.8) and ORR of 22.8 %. A “Post-CKI score” was constructed by combining significant predictors of OS at the multivariate analyses (sex, ECOG PS, disease control with prior immunotherapy), Harrell'C was 0.65, (95 % CI:0.59−0.71). Conclusions: Despite the late-line settings, our findings support the hypothesis that previous immunotherapy might increase the sensitivity of the tumor to the subsequent chemotherapy. The “Post-CKI score” was clinically effective in successfully discriminating three distinct prognostic subgroups of patients after the failure of CKI, representing a possibly useful tool for the tailored decision-making process of advanced treatment-line settings in NSCLC.

Published
2020

79. Immunotherapy in Underrepresented Populations of Patients with Cancer: Do We Have Enough Evidence at Present? A Focus on Patients with Major Viral Infections and Autoimmune Disorders

Author

Antonuzzo, A, Calabrò, F, Quaglino, P, Roila, F, Sebastiani, G, Spina, F, Pasqualetti, G, Cortinovis, D, Tagliaferri, E, Peri, A, Presotto, E, Egidi, M, Giacomelli, L, Farroni, F, Di Maio, M, De Luca, E, Danova, M, Scottè, F, Jordan, K, Bossi, P, Antonuzzo A, Calabrò F, Quaglino P, Roila F, Sebastiani GD, Spina F, Pasqualetti G, Cortinovis D, Tagliaferri E, Peri A, Presotto EM, Egidi MF, Giacomelli L, Farroni F, Di Maio M, De Luca E, Danova M, Scottè F, Jordan K, Bossi P, Antonuzzo, A, Calabrò, F, Quaglino, P, Roila, F, Sebastiani, G, Spina, F, Pasqualetti, G, Cortinovis, D, Tagliaferri, E, Peri, A, Presotto, E, Egidi, M, Giacomelli, L, Farroni, F, Di Maio, M, De Luca, E, Danova, M, Scottè, F, Jordan, K, Bossi, P, Antonuzzo A, Calabrò F, Quaglino P, Roila F, Sebastiani GD, Spina F, Pasqualetti G, Cortinovis D, Tagliaferri E, Peri A, Presotto EM, Egidi MF, Giacomelli L, Farroni F, Di Maio M, De Luca E, Danova M, Scottè F, Jordan K, and Bossi P

Abstract

The safety and activity of immune checkpoint inhibitors have been characterized in interventional and observational studies. However, only small studies have specifically investigated these agents in patients who are excluded or underrepresented in clinical trials, frequently referred to as “special populations” or “underrepresented populations.” These include older adults, those with dysregulated immune activation, patients with a compromised immune function, and those carrying major viral infections, lymphoproliferative diseases, and major organ dysfunctions. Therefore, there remains substantial uncertainty regarding the use of immune checkpoint inhibitors in these specific settings. The Network of Italian Supportive Care in Oncology has carried out a multidisciplinary project, with the contribution of oncologists and other specialists, to retrieve the existing evidence on the use of immunotherapy in patients with solid and hematological cancers with the final aim to provide an expert guidance. The results of this effort are presented in this article, which is focused on patients with major viral infections or those with immune dysregulation/autoimmune diseases, and could be useful to guide decisions in clinical practice and to design prospective clinical trials focusing on the use of immunotherapy in these populations. Implications for Practice: Substantial uncertainty remains regarding the use of immune checkpoint inhibitors in “underrepresented” patients, such as older adults, those with dysregulated immune activation, and patients with a compromised immune function, major viral infections, lymphoproliferative diseases or major organ dysfunctions. The Network of Italian Supportive Care in Oncology has carried out a multidisciplinary project to retrieve the existing evidence on the use of immunotherapy in underrepresented patients with cancer in order provide an expert guidance. The results of this effort, with a focus on patients with major viral infections or

Published
2020

81. ADOPTION OF PATIENT-REPORTED OUTCOMES IN CLINICAL PRACTICE FOR OLDER PATIENTS RECEIVING ACTIVE ANTI-CANCER TREATMENT: IMPACT ON HEALTH-RELATED QUALITY OF LIFE

Author

Zichi, C., primary, De Vita, F., additional, Paparo, J., additional, Salerno, F., additional, Marino, D., additional, Sperti, E., additional, Lacidogna, G., additional, Vignani, F., additional, Dionisio, R., additional, Baratelli, C., additional, Turco, C.G.C., additional, Ballaminut, D., additional, Bellezza, A., additional, Chiotto, P., additional, Ciriolo, G., additional, Comite, R., additional, Codegone, F., additional, Florio, S., additional, Fusco, L., additional, Polimeno, L., additional, Pozzi, D., additional, Zilio, E., additional, Ariu, V., additional, Terziolo, S., additional, and Di Maio, M., additional

Published
2021
Full Text
View/download PDF

84. P59.20 Natural History of KRAS Mutant Non-Small-Cell Lung Cancer in the Immunotherapy Era: A Single-Centre Retrospective Study

Author

Bironzo, P., primary, Jacobs, F., additional, Cani, M., additional, Reale, M.L., additional, Tabbò, F., additional, Olmetto, E., additional, Capelletto, E., additional, Napoli, V., additional, Passiglia, F., additional, Listì, A., additional, Righi, L., additional, Di Maio, M., additional, Novello, S., additional, and Scagliotti, G., additional

Published
2021
Full Text
View/download PDF

86. Prostate cancer awareness among Italian adult males: a national web-based survey

Author

Sighinolfi, M.C., primary, Battaglia, M., additional, Bellardita, L., additional, Castiglioni, S., additional, Dal Moro, F., additional, De Giorgi, U., additional, De Monte, A., additional, Di Maio, M., additional, Gaboardi, F., additional, Gontero, P., additional, Jereczek, B.A., additional, Leonardi, R., additional, Lombardi, E., additional, Madonia, M., additional, Mangiagalli, A., additional, Marenghi, C., additional, Marrocco, W., additional, Masini, C., additional, Miano, R., additional, Polloni, G., additional, Prezioso, D., additional, Ruffini, L., additional, Sabbatini, R., additional, Schips, L., additional, Selli, C., additional, Valdagni, R., additional, Varca, V., additional, Veneziano, P., additional, Calcagnile, T., additional, and Rocco, B., additional

Published
2021
Full Text
View/download PDF

88. 1497P Cancer patients’ awareness about clinical research: The ELPIS study preliminary results

Author

Cagnazzo, C., primary, Franchina, V., additional, Toscano, G., additional, Fagioli, F., additional, Franchina, T., additional, Ricciardi, G.R.R., additional, Antonuzzo, L., additional, Di Costanzo, A., additional, Russo, A., additional, Cusenza, S., additional, Gori, S., additional, Marchetti, F., additional, Tambaro, M., additional, Piccirillo, P., additional, Nanni, O., additional, Delfanti, S., additional, Di Maio, M., additional, D'Ascanio, F., additional, and Adamo, V., additional

Published
2021
Full Text
View/download PDF

89. 1783P Multi-parametric T cells profiling in broncho-alveolar lavage fluid (BAL) and blood from advanced lung cancer patients

Author

Mariniello, A., primary, Tabbò, F., additional, Indellicati, D., additional, Geuna, M., additional, Tesauro, M., additional, Rezmives, N.A., additional, Di Maio, M., additional, Bironzo, P., additional, Reale, M.L., additional, Passiglia, F., additional, Listi, A., additional, Capelletto, E., additional, Carnio, S., additional, Bertaglia, V., additional, Mecca, C., additional, Consito, L.T., additional, De Filippis, M., additional, Bungaro, M., additional, Paratore, C., additional, and Novello, S., additional

Published
2021
Full Text
View/download PDF

90. 763P Treatment response to non-platinum therapies in ovarian cancer patients according to BRCA status: A retrospective analysis of a large multicentric cohort

Author

Giannone, G., primary, Ghisoni, E., additional, Katsaros, D., additional, Scotto, G., additional, De Giorgi, U., additional, Farolfi, A., additional, Borella, F., additional, Ferrero, A., additional, Gemmiti, S., additional, Cosma, S., additional, Villa, M., additional, Tuninetti, V., additional, Turinetto, M., additional, Mittica, G., additional, Zavallone, L., additional, Aglietta, M., additional, Pasini, B., additional, Di Maio, M., additional, and Valabrega, G., additional

Published
2021
Full Text
View/download PDF

91. 1616P Drop in early-stage colorectal cancer diagnoses after COVID-19: Preliminary report from the COVID-DELAY study

Author

Mentrasti, G., primary, Cognigni, V., additional, Di Maio, M., additional, Chiari, R., additional, La Verde, N., additional, Zichi, C., additional, Aimar, G., additional, De Vita, F., additional, Marini, S., additional, Cona, M.S., additional, Pinterpe, G., additional, Pecci, F., additional, Migliore, A., additional, Caravita, E., additional, Rocchi, M.B.L., additional, Bittoni, A., additional, Giampieri, R., additional, Cantini, L., additional, and Berardi, R., additional

Published
2021
Full Text
View/download PDF

93. Correction to: Efficacy and safety of an innovative prolonged-release combination drug in patients with distal renal tubular acidosis: an open-label comparative trial versus standard of care treatments

Author

Bertholet-Thomas, A., Guittet, C., MANSO-SILVAN, M. A., CASTANG, A., Baudouin, V., Cailliez, M., DI Maio, M., GILLION-BOYER, O., GOLUBOVIC, E., HARAMBAT, Jerome, Klein, A., Knebelmann, B., Nobili, F., Novo, R., PODRACKA, L., Roussey-Kesler, G., STYLIANOU, C., GRANIER, L. A., Bordeaux population health (BPH), and Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, GeneralLiterature_REFERENCE(e.g.,dictionaries,encyclopedias,glossaries)
Abstract

The published version of the article unfortunately contained a mistake.

Published
2021
Full Text
View/download PDF

94. IMPACT OF DIFFERENT DOSING STRATEGIES OF NIVOLUMAB IN PATIENTS WITH SOLID TUMORS: ITALIAN SINGLE CENTER ANALYSIS

Author

Gamba, T., primary, Caglio, A., additional, Sacchi, F., additional, Paratore, C., additional, Fazzina, G., additional, Tagini, V., additional, Bellero, M., additional, Masucci, S., additional, Vignani, F., additional, Lacidogna, G., additional, Zichi, C., additional, Aimar, G., additional, Marino, D., additional, Sperti, E., additional, Gasco, A., additional, and Di Maio, M., additional

Published
2021
Full Text
View/download PDF

96. Impact of adoption of patient-reported outcomes in clinical practice on the accuracy of symptom reporting in medical records of cancer patients

Author

Marino, D., Baratelli, C., Guida, G., Turco, C. G. C., Lacidogna, G., Sperti, E., Vignani, F., De Luca, E., Zichi, C., Audisio, M., Ballaminut, D., Bellezza, A., Chiotto, P., Ciriolo, G., Comite, R., Codegone, F., Florio, S., Fusco, L., Polimeno, L., Pozzi, D., Zilio, E., Terzolo, S., and Di Maio, M.

Subjects
Diarrhea, Vomiting, Neoplasms, Humans, Pain, Patient Reported Outcome Measures, Constipation, Fatigue, Medical Records
Abstract

Medical records are a relevant source for real-world evidence. We introduced patient-reported outcomes (PROs) in clinical practice, demonstrating a significant quality-of-life improvement, compared to usual visit. In this secondary analysis, we describe the agreement between patients' and physicians' reports of 5 symptoms. Our hypothesis was that adoption of PROs questionnaire could significantly improve the agreement.Eligible patients were receiving active anti-cancer treatment. Patients in the control group underwent usual visits (group A), while patients of group B, before each visit, filled a PROs paper questionnaire, to provide information about symptoms and toxicities. No specific instructions were provided to physicians to integrate such information in medical records. Agreement between patient and physician evaluations was assessed by Cohen's κ, calculating under-reporting as proportion of toxicities reported by patients but not recorded by physicians.211 patients (412 visits) have been analyzed. For all symptoms, Cohen's κ was better for group B: emesis (0.25 group A vs. 0.36 group B), diarrhea (0.16 vs. 0.57), constipation (0.07 vs. 0.28), pain (0.22 vs. 0.42), fatigue (0.03 vs. 0.08). For all symptoms, although under-reporting was relevant in both groups, it was lower for group B: emesis (75.49% vs. 60.0%, p=0.031), diarrhea (82.89% vs. 50.0%, p0.001), constipation (92.11% vs. 69.57%, p0.001), pain (59.57% vs. 42.31%, p=0.01), fatigue (82.11% vs. 64.10%, p0.001).Adoption of paper PROs allowed a significant reduction in under-reporting of symptoms, but agreement remained suboptimal. Direct integration of electronic PROs could minimize the issue of under-reporting of medical records, increasing their accuracy.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results